Global Cancer Rates Surge as Biotech Innovators Work on New Therapies
Provided By PR Newswire
Last update: Sep 20, 2024
Issued on behalf of Oncolytics Biotech Inc.
VANCOUVER, BC, Sept. 20, 2024 /PRNewswire/ -- USA News Group – Cancer rates are rising globally, and the outlook is particularly concerning for men. A recent global study projects an 84% increase in cancer cases and a 93% rise in cancer deaths among men by 2050. According to Our World in Data, cancer has overtaken cardiovascular diseases as the leading cause of death in several wealthy nations. Despite warnings from the American Cancer Society, which found that 44% of cancer deaths in U.S. adults are linked to lifestyle factors, troubling trends continue. Another study revealed that even light drinking is associated with an increase in cancer deaths among older adults in Britain. Meanwhile, behind the scenes, biotech innovators are developing new targets for improved cancer therapies, driving the next wave of breakthroughs in oncology coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), G1 Therapeutics, Inc. (NASDAQ: GTHX), Arcellx, Inc. (NASDQ: ACLX), Sanofi (NASDAQ: SNY), and Halozyme Therapeutics, Inc. (NASDAQ: HALO).
Read more at prnewswire.com57.75
+0.31 (+0.54%)
0.7256
-0.01 (-1.79%)
54.46
+0.33 (+0.61%)
Find more stocks in the Stock Screener
HALO Latest News and Analysis
6 days ago - ChartmillNASDAQ:HALO is not too expensive for the growth it is showing.HALOZYME THERAPEUTICS INC could be undervalued. NASDAQ:HALO is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced.
6 days ago - ChartmillNASDAQ:HALO appears to be flying under the radar despite its strong fundamentals.Discover HALOZYME THERAPEUTICS INC, an undervalued stock. NASDAQ:HALO showcases solid financial health and profitability while maintaining an appealing valuation.
20 days ago - ChartmillHALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a candidate for high growth investors. Here's why.A fundamental and technical analysis of (NASDAQ:HALO): HALOZYME THERAPEUTICS INC (NASDAQ:HALO) may be suited for high growth investing, we'll explore why in this article.
20 days ago - ChartmillNASDAQ:HALO—A High-Growth Stock Gearing Up for Its Next Upward Move.Based on fundamental and technical analysis of NASDAQ:HALO we ask: Why HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Is a Standout High-Growth Stock in a Consolidation Phase.
